Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
05
03
2024
accepted:
30
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-based next-generation sequencing (NGS). In this study (NCT02866149), ctDNA dynamics were assessed using droplet digital PCR (ddPCR) in 69 MUM patients undergoing tebentafusp treatment. Notably, 61% of patients exhibited detectable ctDNA before treatment initiation, which was associated with shorter overall survival (median 12.9 months versus 40.5 months for patients with undetectable ctDNA; p < 0.001). Patients manifesting a 90% or greater reduction in ctDNA levels at 12 weeks demonstrated markedly prolonged overall survival (median 21.2 months versus 12.9 months; p = 0.02). Our findings highlight the potential of ddPCR-based ctDNA monitoring as an economical, pragmatic and informative approach in MUM management, offering valuable insights into treatment response and prognosis.
Identifiants
pubmed: 39402032
doi: 10.1038/s41467-024-53145-0
pii: 10.1038/s41467-024-53145-0
doi:
Substances chimiques
Circulating Tumor DNA
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8851Informations de copyright
© 2024. The Author(s).
Références
Jager, M. J. et al. Uveal melanoma. Nat. Rev. Dis. Prim. 6, 24 (2020).
doi: 10.1038/s41572-020-0158-0
pubmed: 32273508
Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370–1380 (2019).
doi: 10.1093/annonc/mdz176
pubmed: 31150059
Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med 389, 2256–2266 (2023).
doi: 10.1056/NEJMoa2304753
pubmed: 37870955
pmcid: 11188986
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. 28, 2364–2373 (2022).
doi: 10.1038/s41591-022-02015-7
pubmed: 36229663
pmcid: 9671803
Gerratana, L. et al. Emerging role of genomics and cell-free DNA in breast cancer. Curr. Treat. Options Oncol. 20, 68 (2019).
doi: 10.1007/s11864-019-0667-9
pubmed: 31256282
Cabel, L. et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat. Rev. Clin. Oncol. 15, 639–650 (2018).
doi: 10.1038/s41571-018-0074-3
pubmed: 30050094
Madic, J. et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin. Cancer Res. 18, 3934–3941 (2012).
doi: 10.1158/1078-0432.CCR-12-0309
pubmed: 22645051
Bidard, F. C. et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J. Cancer 134, 1207–1213 (2014).
doi: 10.1002/ijc.28436
pubmed: 23934701
Park, J. J., et al. Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition. Cancers (Basel) 13, 1740 (2021).
Shoushtari, A. N. et al. Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients. Ann. Oncol. 32, S1210 (2021).
doi: 10.1016/j.annonc.2021.08.1702
Mariani, P. et al. Circulating Tumor DNA as a prognostic factor in patients with resectable hepatic metastases of uveal melanoma. Ann. Surg. 278, e827–e834 (2023).
doi: 10.1097/SLA.0000000000005822
pubmed: 36847256
Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021).
doi: 10.1056/NEJMoa2103485
pubmed: 34551229
Cancer, A. J. C. o. In: AJCC Cancer Staging Manual (ed^(eds). 8th edn. Springer (2017).
Postel, M., Roosen, A., Laurent-Puig, P., Taly, V. & Wang-Renault, S. F. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev. Mol. Diagn. 18, 7–17 (2018).
doi: 10.1080/14737159.2018.1400384
pubmed: 29115895
Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842–1853 (2020).
doi: 10.1158/2159-8290.CD-20-0047
pubmed: 32816849
pmcid: 8358981
Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212–6222 (2018).
doi: 10.1158/1078-0432.CCR-18-0386
pubmed: 30093454
Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin. Cancer Res. 24, 1872–1880 (2018).
doi: 10.1158/1078-0432.CCR-17-1341
pubmed: 29330207
pmcid: 5899677
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
doi: 10.1016/S1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
Amirouchene-Angelozzi, N. et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol. Oncol. 8, 1508–1520 (2014).
doi: 10.1016/j.molonc.2014.06.004
pubmed: 24994677
pmcid: 5528590
Chen, P. W. et al. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin. Exp. Metastasis 15, 509–518 (1997).
doi: 10.1023/A:1018479011340
pubmed: 9247253
Luyten, G. P. et al. Establishment and characterization of primary and metastatic uveal melanoma cell Lines. Int J. Cancer 66, 380–387 (1996).
doi: 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F
pubmed: 8621261
Huggett, J. F. et al. The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments. Clin. Chem. 59, 892–902 (2013).
doi: 10.1373/clinchem.2013.206375
pubmed: 23570709
d, M. G., Huggett, J. F. The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020. Clin. Chem. 66, 1012–1029 (2020).
doi: 10.1093/clinchem/hvaa125
Jeannot, E. et al. A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene 39, 2987–2995 (2020).
doi: 10.1038/s41388-020-1174-y
pubmed: 32042112
Zonta, E., et al. Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations. PLoS One 11, e0159094 (2016).